# Nivolumab in Recurrent or Metastatic Salivary Gland Carcinoma of the Head and Neck

> **NCT03132038** · PHASE2 · COMPLETED · sponsor: **UNICANCER** · enrollment: 98 (actual)

## Conditions studied

- Salivary Gland Carcinoma
- Metastatic Cancer
- Recurrent Cancer

## Interventions

- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT03132038
- **Lead sponsor:** UNICANCER
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-24
- **Primary completion:** 2019-01-01
- **Final completion:** 2021-10-20
- **Target enrollment:** 98 (ACTUAL)
- **Last updated:** 2022-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03132038

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03132038, "Nivolumab in Recurrent or Metastatic Salivary Gland Carcinoma of the Head and Neck". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03132038. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*